Luseogliflozin inhibits high glucose-induced TGF-β2 expression in mouse cardiomyocytes by suppressing NHE-1 activity

OBJECTIVE: Sodium-glucose cotransporter-2 (SGLT2) inhibitors exhibit cardioprotective properties in patients with diabetes. However, SGLT2 is not expressed in the heart, and the underlying molecular mechanisms are not fully understood. We investigated whether the SGLT2 inhibitor luseogliflozin exert...

Descripción completa

Detalles Bibliográficos
Autores principales: Osaka, Naoya, Mori, Yusaku, Terasaki, Michishige, Hiromura, Munenori, Saito, Tomomi, Yashima, Hironori, Shiraga, Yoshie, Kawakami, Raichi, Ohara, Makoto, Fukui, Tomoyasu, Yamagishi, Sho-ichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Pre-Clinical Research Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9082751/
https://www.ncbi.nlm.nih.gov/pubmed/35510669
http://dx.doi.org/10.1177/03000605221097490

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9082751/
https://www.ncbi.nlm.nih.gov/pubmed/35510669
http://dx.doi.org/10.1177/03000605221097490

Ejemplares similares